Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Pfizer Inc. Is Stuck in a Trading Range – for Now

By Chris Lau, InvestorPlace Contributor

PFE's latest quarterly earnings report neither inspired nor scared investors away. Pfizer stock is an income play for now. But PFE stock's value will grow as sales of the 25 to 30 new drugs it has in the approval pipeline ramp up in the years ahead.

Allergan plc Stock Becomes a Buy as It Bottoms Out

By Chris Lau, InvestorPlace Contributor

Allergan (AGN) raised its quarterly and yearly outlook but the stock slumped in trading after the earnings announcement. A big write-down is hammering the stock price.

The Good and the Bad News With Biogen Inc Earnings Results

By Chris Lau, InvestorPlace Contributor

Even before Biogen's quarterly report, BIIB stock sank after a series of disappointing clinical results. Investors have to weigh in the good and the bad developments ahead.

Play Into the Seasonal Strength of Anheuser Busch InBev NV (ADR)

By Chris Lau, InvestorPlace Contributor

Anheuser Busch seems to be out of favor as investors treat BUD stock like that of any other consumer company. But with a line of products in high demand with consumers around the globe, the growth ahead for BUD is enormous.

Mylan NV Still Undervalued Despite Unveiling of New Products

By Chris Lau, InvestorPlace Contributor

MYL stock's forward P/E multiples don't reflect the growth potential for the Mylan NV. EpiPen demand and biosimilars will soon give the company a revenue lift.

Load More